argenx SE

ARGX

$50.33B

Large Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸EuropeZWIJNAARDE1.6K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 11, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

7 upcoming, 0 past

⭐Phase 3Next

efgartigimod Phase 3 Results Expected

Mar 11, 2026Efgartigimod101

Primary completion for efgartigimod trial (NCT04225156) in Primary Immune Thrombocytopenia

Source

🎯PDUFA

FDA PDUFA Date efgartigimod alfa (priority)

8/20/2026

For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K

Source

⭐Phase 3

Empasiprubart Phase 3 Results Expected

September 2026~empasiprubart115

Primary completion for Empasiprubart trial (NCT06742190) in Multifocal Motor Neuropathy (MMN)

Source

⭐Phase 3

IVIG (Intravenous Immunoglobulin) Phase 3 Results Expected

September 2026~IVIG (Intravenous Immunoglobulin)115

Primary completion for IVIG (Intravenous Immunoglobulin) trial (NCT06742190) in Multifocal Motor Neuropathy (MMN)

Source

⭐Phase 3

Efgartigimod PH20 SC Phase 3 Results Expected

Sep 30, 2026Efgartigimod PH20 SC12

Primary completion for Efgartigimod PH20 SC trial (NCT06392386) in Generalized Myasthenia Gravis

Source

Phase 2

Empasiprubart IV Phase 2 Results Expected

November 2026~Empasiprubart IV3

Primary completion for Empasiprubart IV trial (NCT06284954) in Dermatomyositis

Source

⭐Phase 3

EFG PH20 SC Phase 3 Results Expected

Dec 1, 2026EFG PH20 SC265

Primary completion for EFG PH20 SC trial (NCT05523167) in Active Idiopathic Inflammatory Myopathy

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Efgartigimod IV

Phase 3

Generalized Myasthenia Gravis

ARGX-113

Phase 3

Pemphigus Vulgaris

Efgartigimod PH20 SC

Phase 3

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EFG PH20 SC

Phase 3

Active Idiopathic Inflammatory Myopathy

IVIG (Intravenous Immunoglobulin)

Phase 3

Multifocal Motor Neuropathy (MMN)

Efgartigimod

Phase 3

Postural Orthostatic Tachycardia Syndrome

empasiprubart

Phase 3

Chronic Inflammatory Demyelinating Polyneuropathy

Prednisone

Phase 3

Bullous Pemphigoid

Empasiprubart IV

Phase 3

Chronic Inflammatory Demyelinating Polyneuropathy

ARGX-119

Phase 2

Amyotrophic Lateral Sclerosis

ARGX-117

Phase 2

Multifocal Motor Neuropathy

efgartigimod PH20 SC in stage B

Phase 2

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

ARGX-119 IV

Phase 2

Spinal Muscular Atrophy (SMA)

Drug Name	Phase	Indication	Designations
Efgartigimod IV	Phase 3	Generalized Myasthenia Gravis	-
ARGX-113	Phase 3	Pemphigus Vulgaris	-
Efgartigimod PH20 SC	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	-
EFG PH20 SC	Phase 3	Active Idiopathic Inflammatory Myopathy	-
IVIG (Intravenous Immunoglobulin)	Phase 3	Multifocal Motor Neuropathy (MMN)	-
Efgartigimod	Phase 3	Postural Orthostatic Tachycardia Syndrome	-
empasiprubart	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy	-
Prednisone	Phase 3	Bullous Pemphigoid	-
Empasiprubart IV	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy	-
ARGX-119	Phase 2	Amyotrophic Lateral Sclerosis	-
ARGX-117	Phase 2	Multifocal Motor Neuropathy	-
efgartigimod PH20 SC in stage B	Phase 2	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	-
ARGX-119 IV	Phase 2	Spinal Muscular Atrophy (SMA)	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ARGX News